Product
Bimatoprost
Aliases
Bimatoprost Ophthalmic, Bimatoprost SR, Bimatoprost (SR)
10 clinical trials
13 indications
Indication
open-angle glaucomaIndication
ocular hypertensionIndication
GlaucomaIndication
Open-angle GlaucomaIndication
Open-AngleIndication
Healthy Control ParticipantsIndication
ScarIndication
Hypopigmented ScarIndication
Hypopigmented SkinIndication
ScarringIndication
HypertrophicIndication
Pigmentation DisorderIndication
BurnsClinical trial
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionStatus: Active (not recruiting), Estimated PCD: 2025-08-09
Clinical trial
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsStatus: Completed, Estimated PCD: 2024-03-07
Clinical trial
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular HypertensionStatus: Completed, Estimated PCD: 2021-11-24
Clinical trial
An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)Status: Completed, Estimated PCD: 2022-05-14
Clinical trial
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy VolunteersStatus: Completed, Estimated PCD: 2023-04-05
Clinical trial
A Randomized ( 1:1), Double-Masked, Multi-Center, Two-Treatment, Single-Period, Parallel Design, Mutiple Dose Bioequivalence Study With Clinical End-Point of Bimatoprost Ophthalmic Solution 0.01% of Mankind Pharma Limited With LUMIGAN (Bimatoprost Ophthalmic Solution) 0.01% of Allergan, Inc., in Subjects With Chronic Open-Angle Glaucoma Or Ocular Hypertension in Both EyesStatus: Completed, Estimated PCD: 2022-08-11
Clinical trial
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous PatientsStatus: Completed, Estimated PCD: 2021-02-03
Clinical trial
Evaluation of Laser-assisted Drug Delivery of Bimatoprost for the Treatment of Hypertrophic Scar Hypopigmentation: A Within Patient-Controlled Trial in Skin of ColorStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Stop Retinal Ganglion Cell Dysfunction StudyStatus: Active (not recruiting), Estimated PCD: 2024-07-01